<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02763254</url>
  </required_header>
  <id_info>
    <org_study_id>CM-2015-01</org_study_id>
    <nct_id>NCT02763254</nct_id>
  </id_info>
  <brief_title>Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas</brief_title>
  <acronym>CIVIC</acronym>
  <official_title>A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cell Medica Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cell Medica Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the
      treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and
      Post-transplant Lymphoproliferative Disease (PTLD) after failing first line treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>1 year</time_frame>
    <description>Best single observed response, complete response (CR) or partial response (PR) per Lugano 2014 Disease Response Criteria, during 12 month follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>3, 6, 9 &amp; 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>3, 6, 9 &amp; 12 months</time_frame>
    <description>Percentage of evaluable patients who achieve a complete response (CR), partial response (PR) or stable disease (SD) per Lugano 2014 Disease Response Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>EBV DNA Viral Load</measure>
    <time_frame>1 year</time_frame>
    <description>Surrogate - Virological response based on reduction in circulating EBV DNA in whole blood and plasma, as measured by polymerase chain reaction (PCR)</description>
  </other_outcome>
  <other_outcome>
    <measure>ORR based on LYRIC</measure>
    <time_frame>1 year</time_frame>
    <description>As assessed by independent radiology committee</description>
  </other_outcome>
  <other_outcome>
    <measure>EBV antigen specific T cell activity</measure>
    <time_frame>1 year</time_frame>
    <description>MoA - as assessed by ELISpot</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Post-transplant Lymphoproliferative Disorder</condition>
  <arm_group>
    <arm_group_label>CMD-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMD-003</intervention_name>
    <description>Autologous EBV-specific T cells</description>
    <arm_group_label>CMD-003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The study will include three primary cohorts, with any of the following EBV+ diseases:

             Cohort A - DLBCL, 1) in first or subsequent relapse, not eligible for autologous
             transplantation following salvage therapy OR 2) relapse following autologous
             transplantation.

             Cohort B - HL, brentuximab vedotin (BV) treatment failure or unable to tolerate BV.

             Cohort C - PTLD, rituximab treatment failure.

          2. Presence of active lymphoma or active PTLD, based on imaging performed within the
             previous 3 months.

          3. Tumor positive for EBV encoded RNA (EBER) based on report from certified laboratory.

          4. Absolute lymphocyte count (ALC) &gt;500/µL

          5. Male or female ≥ 12 years of age

          6. Weight ≥ 35 kg

          7. Eastern Cooperative Oncology Group (ECOG) performance score 0-2, inclusively or Lansky
             score ≥ 60, as age appropriate

          8. Able to understand and comply with the requirements of the study and to provide
             written informed consent or age appropriate assent for pediatric patients.

        Exclusion Criteria:

          1. Known central nervous system (CNS) lymphoma

          2. Primary refractory HL or DLBCL

          3. Bulky disease

          4. Relapse or progression following previous autologous EBV specific T cell treatment.

          5. Use of systemic corticosteroids &gt; 0.5 mg/kg/day prednisolone or equivalent does of
             alternative corticosteroid within 10 days prior to obtaining 200 mL starting material

          6. Positive for HIV, hepatitis B, hepatitis C, syphilis or human T cell leukemia virus
             (HTLV).

          7. Patient is pregnant or lactating

          8. Systemic fungal, bacterial, viral or other infection that is not controlled

          9. Prior allogeneic hematopoietic stem cell transplantation (allo HSCT)

         10. Known history of primary immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kurt Gunter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cell Medica, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shannon Inman</last_name>
    <phone>832-581-4474</phone>
    <email>shannon.inman@cellmedica.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemarie Abary</last_name>
      <phone>626-218-8087</phone>
      <email>rabary@coh.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Budde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Fernanda Fortiz</last_name>
      <phone>202-476-4225</phone>
      <email>MFFORTIZ@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Catherine Bollard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Watkins, RN, BSN</last_name>
      <phone>410-502-6058</phone>
      <email>swatki30@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Ambinder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeffrey Barnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yi Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jia Ruan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Pittsburgh - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie McEvoy</last_name>
      <phone>412-623-3083</phone>
      <email>mcevoycb@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jing-Zhou Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicky Torrano</last_name>
      <phone>832-824-7821</phone>
      <email>vxtorran@txch.org</email>
    </contact>
    <investigator>
      <last_name>Helen Heslop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Claret</last_name>
      <phone>713-792-1044</phone>
      <email>LCClaret@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Yasushiro Oki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epstein-Barr Virus</keyword>
  <keyword>DLBCL</keyword>
  <keyword>PTLD</keyword>
  <keyword>EBV</keyword>
  <keyword>CIVIC</keyword>
  <keyword>HL</keyword>
  <keyword>T cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

